Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors

The Oncologist
Chooi Peng LeeGordon J Rustin

Abstract

This open-label phase I dose-escalation study investigated the safety, efficacy, pharmacokinetics (PK), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) effects of the oral angiokinase inhibitor nintedanib in patients with advanced solid tumors. Nintedanib was administered once daily continuously, starting at 100 mg and later amended to allow evaluation of 250 mg b.i.d. The primary endpoint was maximum tolerated dose (MTD). DCE-MRI studies were performed at baseline and on days 2 and 28. Fifty-one patients received nintedanib 100-450 mg once daily (n = 40) or 250 mg b.i.d. (n = 11). Asymptomatic reversible liver enzyme elevations (grade 3) were dose limiting in 2 of 5 patients at 450 mg once daily. At 250 mg b.i.d., 2 of 11 patients experienced dose-limiting toxicity (grade 3 liver enzyme elevation and gastrointestinal symptoms). Common toxicities included fatigue, diarrhea, nausea, vomiting, and abdominal pain (mainly grade ≤2). Among 45 patients, 22 (49%) achieved stable disease; 7 remained on treatment for >6 months. DCE-MRI of target lesions revealed effects in some patients at 200 and ≥400 mg once daily. Nintedanib is well tolerated by patients with advanced solid malignancies, with MTD defined as 250 mg ...Continue Reading

Citations

Mar 24, 2016·Pharmacology & Therapeutics·Zhuo Li, Yibin Kang
Apr 21, 2016·Journal of Clinical Pharmacology·Claudia DallingerPeter Stopfer
Jun 27, 2017·Expert Opinion on Pharmacotherapy·Antonio RossiEvaristo Maiello
Apr 25, 2019·Clinical Pharmacokinetics·Sven WindClaudia Dallinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Kazuhiko YamadaTomohide Tamura
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ralf-Dieter HofheinzGerd Munzert
Cancer Chemotherapy and Pharmacology
Laura HorsleyCancer Research UK Drug Development Office Phase I clinical trial
© 2021 Meta ULC. All rights reserved